GSK(US:GSK) Jing Ji Guan Cha Wang·2025-11-06 23:14Core Insights - GSK is actively engaging in discussions on hepatitis B during the 8th China International Import Expo, aligning with national health initiatives [1] - The Chinese government has developed a clear action plan for hepatitis prevention and treatment from 2025 to 2030, emphasizing a collaborative approach among various sectors [1] - The focus is shifting towards achieving "functional cure" for chronic hepatitis B, which could significantly reduce liver cancer incidence by 76% [1] - GSK is committed to collaborating with partners in China and globally to expedite the delivery of innovative treatments to patients [1] Group 1 - GSK is conducting discussions on hepatitis B during the 8th China International Import Expo [1] - The National Health Commission has established the "Action Plan for the Prevention and Treatment of Viral Hepatitis (2025-2030)" [1] - The plan aims to integrate medical, insurance, and pharmaceutical sectors to enhance hepatitis management [1] Group 2 - The goal of hepatitis B treatment is evolving towards "functional cure" [1] - Achieving functional cure can lead to a 76% reduction in liver cancer incidence [1] - This approach is expected to alleviate the financial burden on patients and society over the long term [1] Group 3 - GSK's Vice President emphasizes the company's commitment to rapid innovation delivery for Chinese patients [1] - Collaboration with global partners is a key strategy for GSK in addressing hepatitis B [1]